Biocon
Ticker > Company >

Biocon share price

Biocon Ltd.

NSE: BIOCON BSE: 532523 SECTOR: Pharmaceuticals & Drugs  276k   1k   271

328.20
-1.80 (-0.55%)
BSE: 12 May 04:01 PM

Price Summary

Today's High

₹ 335.95

Today's Low

₹ 317.9

52 Week High

₹ 404.6

52 Week Low

₹ 270

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 39403.69 Cr.

Enterprise Value

₹ 40858.79 Cr.

No. of Shares

120.06 Cr.

P/E

64.67

P/B

3.42

Face Value

₹ 5

Div. Yield

0.15 %

Book Value (TTM)

₹  95.99

CASH

₹ 585.7 Cr.

DEBT

₹ 2040.8 Cr.

Promoter Holding

60.64 %

EPS (TTM)

₹  5.08

Sales Growth

6.74%

ROE

1.1 %

ROCE

2.77%

Profit Growth

-95.81 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Biocon Ltd.

Insugen Basalog BIOMAb EGFR CANMAb ALZUMAb KRABEVA TACROGRAF

Index Presence

The company is present in 31 Indices.

NFT150MOM50

Nifty Midcap150 Momentum 50
59201.45
  2533.35 (4.47050456959031%)

NIFTYMIDCAP

NIFTY Midcap 100
55416.05
  2192.7 (4.11980831721417%)

NIFTY500

Nifty 500
22511.4
  835.850000000002 (3.85618819360987%)

NIFTYPHARMA

Nifty Pharma
21102.7
  30.9500000000007 (0.14687911540332%)

NIFTYMIDCAP150

Nifty Midcap 150
20331.5
  735.25 (3.7519933660777%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
18643
  689.25 (3.83903084313861%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
16885.7
  629.400000000001 (3.87172972939722%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
15698.4
  575.75 (3.80720310263083%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
15458.25
  575.85 (3.86933559103371%)

NIFTYHEALTH

Nifty Healthcare Index
13765.5
  92.7000000000007 (0.677988414955255%)

NIFTY200

Nifty 200
13733.8
  516.099999999999 (3.90461275411%)

NFT500EQUAL

Nifty 500 Equal Weight
13296.75
  510.200000000001 (3.99013025405603%)

NIFTYTOTALMCAP

Nifty Total Market index
12640.6
  472.550000000001 (3.88353105057919%)

SHARIAH500

Nifty500 Shariah
6944.9
  239.2 (3.56711454434286%)

NIFTYFULLMIDCAP100

NIFTY FULL MIDCAP 100
5987.56
  -42.7999999999993 (-0.709742038617911%)

NIFTY100ENHESG

NIFTY100 Enhanced ESG
4861.85
  183.6 (3.92454443435046%)

NIFTY100ESG

NIFTY100 ESG
4825.8
  182.2 (3.92367990352311%)

NIFTY100ESGSECT

Nifty100 ESG Sector Leaders
4147
  151.95 (3.80345677776248%)

MIDCAP

S&P Bse Mid Cap
43731.6
  1620.1 (3.84716763829358%)

BSE HC

S&P Bse Healthcare
41599.29
  376.690000000002 (0.913794860101014%)

BSE500

S&P Bse 500
35412.4
  1307.1 (3.83254215620445%)

MID150

S&P Bse 150 MidCap
15213.91
  550.1 (3.75141249102382%)

200EQW

BSE 200 Equal Weight
12506.18
  455.4 (3.77900849571562%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
11318.29
  413.830000000002 (3.79505266652362%)

BSE200

S&P Bse 200
11200.61
  415.620000000001 (3.85368924774154%)

LMI250

S&P Bse 250 LargeMidCap
10590.1
  390.42 (3.82776714563595%)

BSE1000

Bse 1000
10511.56
  392.23 (3.87604712960246%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
10319.66
  72.75 (0.709970127579918%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year6.74%
3 Year1.6%
5 Year3.56%

Profit Growth

1 Year-95.81%
3 Year-24.8%
5 Year-24.7%

ROE%

1 Year1.1%
3 Year10.83%
5 Year8.44%

ROCE %

1 Year2.77%
3 Year11.45%
5 Year9.29%

Debt/Equity

0.1884

Price to Cash Flow

-319.84

Interest Cover Ratio

1.756

CFO/PAT (5 Yr. Avg.)

0.29228769957036

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 60.64 0.00
Dec 2024 60.64 0.00
Sep 2024 60.64 0.00
Jun 2024 60.64 0.00
Mar 2024 60.64 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 74.837 days.
  • Company has a healthy liquidity position with current ratio of 3.9931.
  • The company has a high promoter holding of 60.64%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 44.1451080008243.

 Limitations

  • The company has shown a poor profit growth of -24.796879906375% for the Past 3 years.
  • The company has shown a poor revenue growth of 1.59951711415043% for the Past 3 years.
  • Company has negative cash flow from operations of -123.2.
  • The company is trading at a high PE of 64.67.
  • The company is trading at a high EV/EBITDA of 100.514.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 532.6 510.6 525.4 562.8 643.8
Total Expenditure 480.4 465.7 487.8 531.5 581.8
Operating Profit 52.2 44.9 37.6 31.3 62
Other Income 38.9 41.9 73.5 64.2 62.7
Interest 39.5 55.2 59.7 65.3 56.7
Depreciation 29.8 30.5 30.5 33.8 33
Exceptional Items 0 0 0 607.5 0
Profit Before Tax 21.8 1.1 20.9 603.9 35
Tax 7.8 0.2 17.7 19.9 13.8
Profit After Tax 14 0.9 3.2 584 21.2
Adjusted EPS (Rs) 0.12 0.01 0.03 4.86 0.18

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 1988.4 2028.4 1738.2 1992.9 2127.3
Total Expenditure 1706.5 1717.2 1677.1 1972.1 1911.6
Operating Profit 281.9 311.2 61.1 20.8 215.7
Other Income 205.8 151.5 187.2 274.1 240
Interest 1.2 0.4 0.4 69.6 198.8
Depreciation 98 103.5 108.2 116.9 121.1
Exceptional Items 159.7 0 0 2862.8 14.5
Profit Before Tax 548.2 358.8 139.7 2971.2 150.3
Tax 111.9 78.3 53.6 122.8 31
Net Profit 440.9 280.5 86.1 2848.4 119.3
Adjusted EPS (Rs.) 3.64 2.34 0.72 23.72 0.99

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 600 600 600.3 600.3 600.3
Total Reserves 6937.3 7307.1 7492.6 10315.7 10312
Borrowings 0.7 0 75.9 1297.7 2040.8
Other N/C liabilities -134.7 -30 -10.7 95.4 116.5
Current liabilities 728 550.2 590.9 698 691.2
Total Liabilities 8131.3 8427.3 8749 13007.1 13760.8
Assets
Net Block 720.7 728.6 804.7 899.4 900.4
Capital WIP 151.9 164.6 270.3 328.9 545
Intangible WIP 0 14.6 14.6 14.6 14.6
Investments 4814 5073.4 5017.8 8949.8 9255.6
Loans & Advances 280.9 150.5 154.2 159 204.1
Other N/C Assets 80.1 126.3 85.2 89.4 81.1
Current Assets 2083.7 2169.3 2402.2 2566 2760
Total Assets 8131.3 8427.3 8749 13007.1 13760.8
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 559.9 358.8 139.7 2971.2 150.3
Adjustment -68.1 117.8 108.3 -2726.9 112.3
Changes in Assets & Liabilities -14 156 -172 16.1 -358.3
Tax Paid -90.7 -61.3 -28.4 -41.1 -27.5
Operating Cash Flow 387.1 571.3 47.6 219.3 -123.2
Investing Cash Flow -188.9 -720.6 -302.1 -1173.1 -294.7
Financing Cash Flow -128.9 27.8 112 1039.4 343.6
Net Cash Flow 69.3 -121.5 -142.5 85.6 -74.3

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 60.64 60.64 60.64 60.64 60.64
dev mazumdar 0.08 0.08 0.08 0.08 0.08
glentec international 19.76 19.76 19.76 19.76 19.76
kiran mazumdar shaw 40.36 40.36 40.36 40.36 40.36
ravi rasendra mazumdar 0.44 0.44 0.44 0.44 0.44
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 39.36 39.36 39.36 39.36 39.36
arun suresh chandavarkar 1.10 1.10 1.10 1.10 1.10
beneficial holdings under... 0.46 0.46 0.46 0.46 0.46
investor education and pr... 0.01 0.01 - 0.01 0.01
kotak equity opportunitie... - 1.55 - - 1.28
lici ulip-growth fund - - 5.09 - 5.34
nippon life india trustee... - - - - 1.25
sbi healthcare opportunit... - - - 3.17 3.43
kotak balanced advantage ... - - - 1.49 -
life insurance corporatio... - - - 5.34 -
investor education and pr... - - 0.01 - -
kotak esg opportunities f... - - 1.46 - -
sbi arbitrage opportuniti... - - 2.43 - -
lici child fortune plus g... 4.41 4.94 - - -
sbi contra fund 2.74 2.72 - - -
quant mutual fund - quant... 1.24 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Biocon informs about corporate presentation 12 May, 11:23 AM Biocon reports two-fold jump in Q4 consolidated net profit 9 May, 2:41 PM Biocon informs about investor presentation 9 May, 10:00 AM Biocon - Quaterly Results 8 May, 7:37 PM Biocon - Quaterly Results 8 May, 7:37 PM Biocon informs about press release 5 May, 9:58 AM Biocon’s arm secures multiple market access agreements for Yesintek 5 May, 9:28 AM Biocon informs about company statement 26 Apr, 12:23 PM Biocon gets nod to raise Rs 4,500 crore 24 Apr, 9:40 AM Biocon raises Rs 600 crore through commercial papers 23 Apr, 10:28 AM Biocon's arm inks settlement and license agreement with Regeneron 15 Apr, 12:51 PM Biocon informs about press release 15 Apr, 9:43 AM Biocon’s US arm recalling 2,184 bottles of medication to treat high cholesterol 11 Apr, 3:29 PM Biocon’s arm gets USFDA’s nod for Everolimus Tablets 11 Apr, 10:22 AM Biocon informs about press release 10 Apr, 9:41 AM Biocon’s arm gets USFDA’s approval for Jobevne 10 Apr, 9:11 AM Biocon gets nod to raise up to Rs 600 crore through commercial papers 5 Apr, 12:30 PM Biocon’s arm gets USFDA’s nod for Norepinephrine Bitartrate Injection 24 Mar, 11:55 AM Biocon informs about disclosure 24 Mar, 9:50 AM Biocon’s arm enters into strategic collaboration agreement with Civica 7 Mar, 9:36 AM Biocon informs about analyst meet 6 Mar, 4:46 PM Biocon’s arm gets USFDA’s nod for Lenalidomide Capsules, Dasatinib Tablets, Rivaroxaban Tablets 5 Mar, 11:12 AM Biocon informs about newspaper advertisements 28 Feb, 4:27 PM Biocon informs about press release 28 Feb, 9:22 AM Biocon launches GLP-1 in United Kingdom 28 Feb, 9:09 AM Biocon’s arm launches Yesintek (ustekinumab-kfce) in United States 25 Feb, 9:29 AM Biocon’s arm gets marketing authorization for YESINTEK 18 Feb, 11:22 AM Biocon informs about updates 18 Feb, 9:17 AM Biocon informs about corporate presentation 3 Feb, 5:07 PM Biocon reports 89% drop in Q3 consolidated net profit 31 Jan, 12:25 PM Biocon informs about presentation of earnings call 31 Jan, 11:11 AM Biocon gets nod to acquire stake in Biocon Biologics 31 Jan, 9:16 AM Biocon - Quaterly Results 30 Jan, 8:12 PM Biocon - Quaterly Results 30 Jan, 8:12 PM Biocon’s S&P Global ESG score improves to 69 for 2024 27 Jan, 11:43 AM Biocon informs about issuance of CP 27 Jan, 9:58 AM Biocon informs about press release 27 Jan, 9:24 AM USFDA classifies insulins facilities of Biocon’s arm as voluntary action indicated 13 Jan, 10:30 AM Biocon’s arm secures approval from PMDA for Ustekinumab BS subcutaneous injection 7 Jan, 12:57 PM Biocon informs about update 7 Jan, 9:48 AM Biocon’s arm secures approval for Tacrolimus capsule from NMPA 3 Jan, 10:59 AM Biocon informs about investor release 30 Dec, 9:51 AM Biocon, Zentiva get nod for Liraglutide in European Union 24 Dec, 11:28 AM Biocon informs about disclosure 24 Dec, 10:04 AM Biocon informs about analyst meet 11 Dec, 4:43 PM Biocon informs about meeting conducted with institutional investors 11 Dec, 4:37 PM Biocon informs about press release 11 Dec, 9:56 AM Biocon sells stake in Syngene International 10 Dec, 5:59 PM Biocon gets EIR with VAI status from USFDA for Bengaluru API facility 9 Dec, 10:23 AM Biocon reports 84% fall in Q2 consolidated net profit 31 Oct, 2:26 PM

Biocon Stock Price Analysis and Quick Research Report. Is Biocon an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Biocon and its performance over the period of time. Biocon stock price today is Rs 328.15.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Biocon cash from the operating activity was Rs -123.2 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Biocon has a Debt to Equity ratio of 0.1884 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Biocon , the EPS growth was -95.8116 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Biocon has OPM of 10.1396135946975 % which is a bad sign for profitability.
     
  • ROE: Biocon have a poor ROE of 1.1027 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Biocon is Rs 328.15. One can use valuation calculators of ticker to know if Biocon share price is undervalued or overvalued.
Last Updated on:
Brief about Biocon

Biocon Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Biocon Ltd. is a leading biopharmaceutical company in India that specializes in the development and manufacturing of biosimilars, novel biologics, and complex small molecules.  We will provide a comprehensive stock analysis of Biocon Ltd. for long-term stock investors.

Biocon Ltd. Share Price 

Biocon's share price has been performing well in recent years, with a steady growth trend. The company's share price is influenced by various factors such as market conditions, industry trends, and company-specific news. Ticker pre-built screening tools can help you keep track of Biocon's share price and compare it with its peers.

Biocon Ltd. Balance Sheet 

Biocon's balance sheet provides insights into the company's financial health and its ability to meet its financial obligations. Our premium features, such as DCF Analysis, BVPS Analysis, and DuPont analysis, can help you calculate the fair value of Biocon's stock based on its balance sheet. By analyzing the company's assets, liabilities, and equity, you can gain a better understanding of its financial position and make informed investment decisions.

Biocon Ltd. Annual Report 

Biocon's annual report provides a comprehensive overview of the company's financial performance, business strategy, and future outlook. You can download Biocon's annual reports from Ticker and analyze them to gain insights into the company's operations and growth prospects. 

Biocon Ltd. Dividend 

Biocon has a consistent track record of paying dividends to its shareholders. The company's dividend payout ratio and yield can provide insights into its financial health and growth prospects. By analyzing Biocon's dividend history and payout policies, you can make informed decisions about investing in the company's stock.

Biocon Ltd. Quarterly Results 

Biocon's quarterly results provide insights into its financial performance and growth prospects. Our premium features, such as earnings multiple approach and DuPont analysis, can help you analyze Biocon's quarterly results and calculate its fair value. By comparing Biocon's quarterly results with its peers and tracking its progress over time, you can make informed investment decisions.

Biocon Ltd. Stock Price 

Biocon's stock price is influenced by various factors such as market conditions, industry trends, and company-specific news. Our pre-built screening tools can help you keep track of Biocon's stock price and compare it with its peers. By analyzing Biocon's stock price trends and market conditions, you can make informed investment decisions.

Biocon Ltd. Price Chart 

Biocon's price chart provides a visual representation of its stock price trends over time. You can use our pre-built screening tools to analyze Biocon's price chart and compare it with its peers. By analyzing Biocon's price chart, you can gain insights into its stock price trends and make informed investment decisions.

Biocon Ltd. News 

Biocon's news provides insights into its business operations, growth prospects, and industry trends. You can use our pre-built screening tools to keep track of Biocon's news and analyze its impact on the company's stock price. By staying up-to-date with Biocon's news, you can make informed investment decisions.

Biocon Ltd. Concall Transcripts 

Biocon's concall transcripts provide insights into its management's views on the company's financial performance, business strategy, and future outlook. You can download Biocon's concall transcripts from Ticker and analyze them to gain insights into the company's operations and growth prospects. By analyzing Biocon's concall transcripts, you can make informed investment decisions.

Biocon Ltd. Investor Presentations 

Biocon's investor presentations provide insights into its business operations, growth prospects, and industry trends. You can download Biocon's investor presentations from Ticker and analyze them to gain insights into the company's operations and growth prospects. By staying up-to-date with Biocon's investor presentations, you can make informed investment decisions.

Biocon Ltd. Promoters 

Biocon's promoters are highly experienced professionals with a proven track record in the biopharmaceutical industry. By analyzing Biocon's promoters and their past performance, you can gain insights into the company's business operations and growth prospects. 

Biocon Ltd. Shareholders 

Biocon's shareholders are a diverse group of investors with different investment objectives and risk profiles. By analyzing Biocon's shareholders and their investment patterns, you can gain insights into the company's stock price trends and growth prospects.Ticker pre-built screening tools can help you compare Biocon's shareholders with its peers and track their progress over time.

Biocon Ltd. ROCE

The Return on Capital Employed (ROCE) is a fundamental financial ratio that measures a company's profitability and efficiency in utilizing its capital. Biocon Ltd.'s ROCE indicates how well the company generates profits from the capital employed in its operations. This ratio is obtained by dividing the company's operating profit by its capital employed. To view Biocon Ltd.'s ROCE data, refer to the financials table or ratio section on this page.

Biocon Ltd. EBITDA

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. Biocon Ltd.'s EBITDA reflects its operating performance by excluding non-operating expenses. EBITDA is a useful metric for comparing companies' profitability and efficiency. To access Biocon Ltd.'s EBITDA data, refer to the financials table or ratio section provided on this page.

Biocon Ltd. DPS

DPS refers to Dividends Per Share, which indicates the amount of money paid to shareholders for each share owned. Biocon Ltd.'s DPS measures the company's willingness and ability to distribute profits to its shareholders. Investors often consider DPS when evaluating the income potential of a stock. To find Biocon Ltd.'s DPS data, refer to the financials table or ratio section featured on this page.

Biocon Ltd. EPS

EPS, or Earnings Per Share, is a financial metric that shows the profitability of a company on a per-share basis. Biocon Ltd.'s EPS reveals the portion of its profit allocated to each outstanding share. This ratio is significant for investors as it helps determine the value of a stock and its potential for growth. To access Biocon Ltd.'s EPS data, refer to the financials table or ratio section provided above. 

Biocon's Reserves Stability

Biocon has consistently strengthened its financial position as seen in its reserves, from Rs 6,937.30 Cr in Mar 2020 incrementally rising to Rs 10,312 Cr by Mar 2024. This stability in reserves is a testament to Biocon's capability to reinvest and fund its operations effectively.

Biocon Balance Sheet and Borrowings Insight

From the balance sheet of Biocon, we observe minimal borrowings at Rs 0.70 Cr in Mar 2020, which sees a notable increase to Rs 2,040.80 Cr by Mar 2024. This strategic shift in leveraging for growth could indicate Biocon's proactive approach to capital financing.

Biocon's Asset Growth

The total assets of Biocon have shown a positive trajectory, climbing from Rs 8,131.30 Cr in Mar 2020 to Rs 13,760.80 Cr in Mar 2024. Investments experience a notable jump, with a highlight on Mar 2023's figure at Rs 8,949.80 Cr, reflecting Biocon's focus on long-term asset accumulation and potential growth avenues.

Current Assets Surge in Biocon

Biocon's liquidity appears robust with current assets expanding from Rs 2,083.70 Cr in Mar 2020 to Rs 2,760 Cr by Mar 2024, illustrating improved operational efficiency and asset management.

This analysis is based on Biocon's standalone balance sheet data, giving a snapshot of the company's financial standing without suggesting any investment action.

In the realm of stock analysis, integrating such financial evaluations with broader market indicators and sector performance, as well as analyzing NSE/BSE index trends, can enhance insights for investors and market spectators analyzing companies like Biocon.

Read More
X